ClinicalTrials.gg
Enrolling by invitationNCT07420803Updated Oct 19, 2026

A Study Of Auricular Transcutaneous Vagus Nerve Stimulation In Chronic Dizziness

An interventional study of Sham Device and Auricular transcutaneous vagus nerve stimulation in Chronic Dizziness and Persistent Postural Perceptual Dizziness, sponsored by Mayo Clinic. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment

How we know

Updated Oct 19, 2026Now Enrolling by invitationGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 78 studies in Dizziness with a site in United States — 16 open to participants now, 19 under way, 1 of them phase 3. Dizziness · United States.

Planned enrollment
23rd of 68
60 · median 35
Started
2026
with 2 others
No phase
51 of 78
13 open now
Primary completion
2027-03
later than 9 of 18 live
Registered
77th of 78
by date
Lead sponsor
2 of 78
Mayo Clinic

Among the 78 studies in Dizziness with a site in United States, this one is the 23rd largest by planned enrollment of the 68 interventional ones that give a count, is one of 3 that started in 2026, is one of 51 with no phase, reaches primary completion later than 9 of the 18 other live ones, and was the 77th registered.

Dizziness

228 studies on the registry are indexed under Dizziness; 57 are open to participants now.

Browse Dizziness studies →

Open to participants now

16 of the 78 studies in Dizziness with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 28 Dizziness studies recruiting now, 11 (39%) set no upper age limit and 11 (39%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Dizziness with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to measure the change in dizziness, as measured by change in Dizziness Handicap Inventory (DHI) score, following a 4-week treatment period with auricular transcutaneous vagus nerve stimulation (aTVNS).

03

Conditions studied

  • Chronic Dizziness
  • Persistent Postural Perceptual Dizziness

Browse trials for

Keywords

  • Vagus Nerve Stimulation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-75, Persistent Postural-Perceptual Dizziness (PPPD) diagnosis per International Classification of Vestibular Disorders (ICVD).
  • Persistent dizziness ≥3 months and at least 1 dizziness exacerbation/day during 2-week run-in.
  • On stable medications/therapy for ≥4 weeks prior to baseline (if any).

Exclusion criteria

Exclusion Criteria:

  • Uncompensated peripheral/central vestibular deficit, sensory-afferent or cerebellar ataxia.
  • Cardiac disease (coronary disease, unstable arrhythmia), recurrent syncope (>1 in past 12 months).
  • Neck surgery, vagotomy, or any condition interfering with vagal stimulation.
  • Pregnancy.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Auricular transcutaneous vagus nerve stimulation

    The vagus nerve stimulation group will perform two sessions per day (morning and evening), each lasting approximately 30 minutes, for a total of 1 hour of auricular transcutaneous vagus nerve stimulation. This arm will continue using the active treatment for 8 weeks.

    Other: Auricular transcutaneous vagus nerve stimulation

  • Sham comparator
    Sound sham electrodes

    The sham control group will will perform two sessions per day (morning and evening), each lasting approximately 30 minutes, for a total of 1 hour of daily stimulation using the sham device. After 4 weeks, the sham control group will begin active auricular transcutaneous vagus nerve stimulation for 4 weeks.

    Other: Sham Device · Other: Auricular transcutaneous vagus nerve stimulation

Interventions

  • OtherSham Device

    The sham control uses the same stimulation devices as the active group, but with modified electrodes that do not emit electrical current. Instead, they produce a mechanical vibration or clicking sensation that mimics the feeling of stimulation without delivering current to the skin.

  • OtherAuricular transcutaneous vagus nerve stimulation

    The Parasym AVNT is a noninvasive, transcutaneous auricular vagus nerve stimulator (tVNS) designed to deliver low-level electrical stimulation to the auricular branch of the vagus nerve through the skin of the outer ear. The stimulator produces mild, pulsed electrical currents typically ranging from 0.1 to 5.0 milliampere (mA) at frequencies between 20-30 Hz and pulse widths of approximately 200-300 μs. The stimulation intensity is adjusted individually to produce a light tingling sensation without discomfort or visible muscle contraction.

06

What researchers measure

Primary outcomes

  1. Change in Dizziness Handicap Inventory (DHI) score

    The Dizziness Handicap Inventory (DHI) is a 25-item questionnaire assesses physical, emotional, and functional aspects of dizziness. Each of the 25 questions has three answers: "Always" (4 points), "Sometimes" (2 points), or "No" (0 points). Scores are summed for a total from 0 (no disability) to 100 (maximum disability).

    Time frame: Baseline, 4 weeks

Secondary outcomes

  1. Change in Anxiety (HADS-A)

    The Hospital Anxiety and Depression (HAD) is a self-reported 14 item questionnaire asking participants to reflect on their mood in the past week. . Each item is rated on a 4-point scale, for a total score ranging from 0-21 for each subscale. A higher score indicates higher distress. Clinically meaningful change is defined as a ≥2-3-point reduction.

    Time frame: Baseline, 4 weeks and 8 weeks

  2. Change in Postural Sway

    Postural sway will be measured using Computerized Dynamic Posturography. A ≥10-15% reduction will be considered a meaningful improvement.

    Time frame: Baseline, 4 weeks and 8 weeks

  3. Weekly averages of dizzy-day frequency

    Frequency of dizzy days will be tracked via patient treatment diary

    Time frame: Through end of study, approximately 8 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Yap JYY, Keatch C, Lambert E, Woods W, Stoddart PR, Kameneva T. Critical Review of Transcutaneous Vagus Nerve Stimulation: Challenges for Translation to Clinical Practice. Front Neurosci. 2020 Apr 28;14:284. doi: 10.3389/fnins.2020.00284. eCollection 2020. PubMed 32410932 ↗
  • Yakunina N, Kim SS, Nam EC. Optimization of Transcutaneous Vagus Nerve Stimulation Using Functional MRI. Neuromodulation. 2017 Apr;20(3):290-300. doi: 10.1111/ner.12541. Epub 2016 Nov 29. PubMed 27898202 ↗
  • Trinidade A, Cabreira V, Goebel JA, Staab JP, Kaski D, Stone J. Predictors of persistent postural-perceptual dizziness (PPPD) and similar forms of chronic dizziness precipitated by peripheral vestibular disorders: a systematic review. J Neurol Neurosurg Psychiatry. 2023 Nov;94(11):904-915. doi: 10.1136/jnnp-2022-330196. Epub 2023 Mar 20. PubMed 36941047 ↗
  • Staab JP, Ruckenstein MJ. Expanding the differential diagnosis of chronic dizziness. Arch Otolaryngol Head Neck Surg. 2007 Feb;133(2):170-6. doi: 10.1001/archotol.133.2.170. PubMed 17309987 ↗
  • Staab JP, Eckhardt-Henn A, Horii A, Jacob R, Strupp M, Brandt T, Bronstein A. Diagnostic criteria for persistent postural-perceptual dizziness (PPPD): Consensus document of the committee for the Classification of Vestibular Disorders of the Barany Society. J Vestib Res. 2017;27(4):191-208. doi: 10.3233/VES-170622. PubMed 29036855 ↗
  • Popkirov S, Stone J, Holle-Lee D. Treatment of Persistent Postural-Perceptual Dizziness (PPPD) and Related Disorders. Curr Treat Options Neurol. 2018 Oct 13;20(12):50. doi: 10.1007/s11940-018-0535-0. PubMed 30315375 ↗
  • Popkirov S, Staab JP, Stone J. Persistent postural-perceptual dizziness (PPPD): a common, characteristic and treatable cause of chronic dizziness. Pract Neurol. 2018 Feb;18(1):5-13. doi: 10.1136/practneurol-2017-001809. Epub 2017 Dec 5. PubMed 29208729 ↗
  • Nada EH, Ibraheem OA, Hassaan MR. Vestibular Rehabilitation Therapy Outcomes in Patients With Persistent Postural-Perceptual Dizziness. Ann Otol Rhinol Laryngol. 2019 Apr;128(4):323-329. doi: 10.1177/0003489418823017. Epub 2019 Jan 4. PubMed 30607985 ↗
  • Frangos E, Ellrich J, Komisaruk BR. Non-invasive Access to the Vagus Nerve Central Projections via Electrical Stimulation of the External Ear: fMRI Evidence in Humans. Brain Stimul. 2015 May-Jun;8(3):624-36. doi: 10.1016/j.brs.2014.11.018. Epub 2014 Dec 6. PubMed 25573069 ↗
  • Eren OE, Filippopulos F, Sonmez K, Mohwald K, Straube A, Schoberl F. Non-invasive vagus nerve stimulation significantly improves quality of life in patients with persistent postural-perceptual dizziness. J Neurol. 2018 Oct;265(Suppl 1):63-69. doi: 10.1007/s00415-018-8894-8. Epub 2018 May 21. PubMed 29785522 ↗
  • Edelman S, Mahoney AE, Cremer PD. Cognitive behavior therapy for chronic subjective dizziness: a randomized, controlled trial. Am J Otolaryngol. 2012 Jul-Aug;33(4):395-401. doi: 10.1016/j.amjoto.2011.10.009. Epub 2011 Nov 21. PubMed 22104568 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.

Of 84 non-industry interventional studies with no phase under Dizziness, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 42. This study's planned 12 months is below that.

Counting every sponsor, half of 92 studies reached it within 19 months; a quarter within 8 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Feb 19, 2026
StartActual
Mar 23, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Enrolling by invitation
changed Oct 19, 2026
Contact
No study contact listed any more: removed c•••@mayo.edu · •••2945
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Recruiting→Enrolling by invitation
    Contact No study contact listed any more: removed c•••@mayo.edu · •••2945
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07420803
Lead sponsor
Mayo Clinic
Responsible party
Colton T. Clayton (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Feb 19, 2026
Start date
Mar 23, 2026
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Oct 19, 2026

Study contacts

Colton Clayton, Au.D., Ph.D.
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion